Following federal efforts like the drug price reforms in the Inflation Reduction Act, some states have also taken it into their own hands to curb the prices of drugs.
On Friday, Colorado’s Prescription Drug Affordability Board voted to set an upper payment limit on Amgen’s arthritis drug Enbrel.
The vote starts a likely six-month process of discussion and gathering data to decide on what that limit will be. The board could also decide not to move forward with an upper-limit payment at any point in the process. The board will hold multiple public hearings over the following months.
The board previously voted on Feb. 16 that Enbrel was unaffordable for Colorado patients. A drug affordability report put together by the board noted that patients with commercial insurance pay an average annual out-of-pocket cost of $3,980 in 2022. In data collected for the report, a little over 71%…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
